Abstract
3707 Background: Over the last decade significant improvements in the outcome for patients with advanced CRC has been achieved. We have reviewed the prospective CRC database at our hospital from 1992 to 2001 to explore whether the availability of new chemotherapy drugs (irinotecan and oxaliplatin) and surgical advances has impacted on survival. Method: Two time periods were analysed: 1/1/92- 31/12/97 & 1/1/98–12/31/01 reflecting the availability of these new drugs in Australia. Two distinct patient groups for each period were analysed; advanced disease (Ad) at diagnosis & patients with Dukes A, B & C disease (abc) at recurrence. Results: There were a total of 541 cases diagnosed with advanced or recurrent CRC available for baseline characteristics. Treatment received is shown in table 1. & has both altered & increased with time, although overall chemotherapy use remains relatively low. The percentage of relapsing v advanced disease reduced over time. The overall 18 month survivals pre & post 98 are as fol...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
